For years, scientists have been researching methods to restore the skin’s elasticity, in hopes to reduce and prevent wrinkles in any skin type. Elastin, a protein in connective tissue that permits tissues in the body to resume their shape after stretching or contracting with regular movement, begins to diminish by the age of 12 or 13 when the body decreases production. As a result, the elastin fibers begin to deteriorate. This leads, over time, to the typical signs of aging, such as fine lines, wrinkles and sagging.
On Monday, Revance Therapeutics, a biopharmaceutical research company based in California, released a new product called
Relastin™, the first product to clinically demonstrate an increase of elastin in the skin. It is said to restore a youthful complexion by penetrating the skin and working with the skin’s cells to promote new elastin growth.
A
press release by
Revance Therapeutics claims that clinical studies with
Relastin™ resulted in a visible difference in 84% of studied subjects following four weeks of testing. The new topical treatment has been shown to hydrate, tighten and smooth the skin in a manner similar to cosmetic injectables and other more invasive treatments.Relastin™ is released as Eye Silk for the under-eye area and Skin Revitalizer for all-over facial use.
Niqeuette Hunt, vice president of cosmetic and OTC products for Revance Therapeutics, is excited about the product’s release. "Relastin™ works from the inside out to foster the restoration of elastin and create a healthier, more youthful appearance,” she says. “Many products have claimed to be ‘cosmetic breakthroughs,’ but Relastin’s™ clinical studies prove remarkable effectiveness.”
According to
Revance Therapeutics, clinical data shows that skin treated with the patent-pending Zinc Firming Complex™ found exclusively in Relastin™ contained more elastin than untreated skin. Following two weeks of testing, users of the product noted visible differences and experienced a decrease in dark circles, a reduction in eye puffiness and minimized fine lines and wrinkles.
If Relastin™ lives up to the claims of the clinical trials, other heavy-hitters in the cosmetic industry may have a run for their money. A topical cream that boosts elastin production would have a more permanent effect than current popular treatments for wrinkles. Rather than freezing the muscles with
Botox® Cosmetic, or plumping the wrinkles with
dermal fillers, Relastin™ is said to address the issue at its root. While this could be the next fountain of youth, it is important to hold out on further studies and trials to prove the product’s capabilities.
Earlier this month Merz Pharmaceuticals, a North Carolina-based company, announced the FDA approval of Xeomin® (incobotulinumtoxinA). Xeomin® is a botulinum toxin type A-based drug that is used to treat patients with blepharospasm (eye spasms) or cervical dystonia (neck spasms).
